The Effect of Low-dose Atropine on Sympathetic Blockade in Spinal Cesarean Section Patients

Sponsor
Abant Izzet Baysal University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05892913
Collaborator
(none)
60
2
6.1

Study Details

Study Description

Brief Summary

The most common side effect in cesarean section surgeries performed under spinal anesthesia is hypotension, which is seen in over 80% and can cause significant morbidity for the mother and fetus. This side effect results from the sympathetic blocking effect, which also causes bradycardia.

A combined approach is supported in the prevention and treatment of hypotension, which recommends adequate fluid support, low-dose spinal anesthesia, and appropriate vasopressor (such as ephedrine, and phenylephrine) and, if bradycardia develops, the use of atropine as a parasympatholytic agent.

In this study, the investigators planned to investigate the possible benefits of preemptive administration of atropine, the dose of which is calculated in proportion to the patient's weight, as soon as a 10% decrease in heart rate is detected, in order to balance the sympathetic blockade due to spinal anesthesia in cesarean section operations.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Our study was approved by the Ethics Committee of Bolu Abant Izzet Baysal University, ASA Ι-ΙΙ, ages 18-40, weight 55-105 kg, height 150-175 cm, with an indication for elective cesarean section, and informed consent will be obtained for the study. Sixty pregnant patients at term scheduled for cesarean delivery under spinal anesthesia will be included.

Those who do not require drug administration with fluid therapy, whose hemodynamic changes are within acceptable range, have systemic disease (Diabetes, COPD, Hypertension), have BMI>34, have a diagnosis of preeclampsia/eclampsia or multiple pregnancy, have pathology in the fetus, have hematological problems such as Rh incompatibility, patients with hypersensitivity to local anesthetics and who are in a position to be a contraindication to regional anesthesia applications will be excluded from the study.

Dexamethasone 4 mg IV for antiemetic purposes was planned for all patients as premedication before the intervention. It was planned to record systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MBP), heart rate (HR), oxygen saturation (SpO2) and respiratory rates by noninvasive method by monitoring the patients with the Mindrey device. In all cases, 2 vascular accesses will be opened with an 18 G (Gauge) intravenous cannula. Intravenous pre-loading was planned for all cases, with 300 cc 0.9% NaCl removed in 15 minutes preoperatively.

Patients will be divided into 2 groups by online randomization method.(Studyrandomizer.com) Fixed dose local anesthetic will be preferred in both groups. After all cases are placed on the operating table and given an anatomical position suitable for spinal anesthesia in a sitting position, skin cleaning will be performed under sterile conditions in the area where the intervention will be performed. Appropriate intervertebral space (L3-L4) will be determined and when the free flow of CSF will be seen after entering the subarachnoid space with a sterile 25-27 G pencil point spinal needle (Egemen/ISTANBUL/TURKEY), 15 mg (2.5 mL) pure (isobaric 0.5% bupivacaine( Marcaine 0.5%/Astra Zeneca/England) ) will be applied. After the application, the patient will placed in the supine position and it will be planned to administer 3 L/min O2 by nasal cannula. After spinal anesthesia, it will planned to start 5 ml/kg/hour 0.9% NaCl solution (Neofleks/Ankara/Turkey) as a maintenance fluid for the patients in both groups during the operation.

In both groups, SBP, DBP, MBP, HR and SpO2 measurements will be recorded at 1, 4, 7, 9, 12, 15, 30, 45, 60, 120 and 240 minutes after the patient is placed left lateral tilt position on the table. After the spinal injection, sensory and motor block levels will be recorded every 3 minutes in the first 15 minutes, and then at the 20th, 25th, 30th, 45th and 60th minutes. It has planned to evaluate the level of sensory block as a dermatome level with the hot-cold test, and motor block by using the Bromage Scale.

The preoperative SBP, DBP, MBP, HR, SpO2 will be recorded before hydration and before spinal anesthesia of the patients will be taken as the baseline value.

For sympathetic blockade (SBP<80) developed in patients in the ephedrine group, a bolus dose of 5 mg/mL ephedrine will be used and repeated if necessary. In case of development of bradycardia (<65/min) in this group, Atropine 0.5 mg/mL will be planned to be administered and repeated if necessary.

In the atropine group, it was planned to administer 0.5 mg/4mL diluted atropine in 20 seconds(10mcg/kg), as a slow bolus as bradycardia would expected (10% reduction in peak heart rate after spinal anesthesia). Also in Atropine group if SBP<80 despite slow dose atropine administration it will be planed to give efedrine. And for bradicardia (HR<65/min) it will be planed to give Atropine 0.5 mg/mL.

The differences between total ephedrine&Atropine consumption, HR,SBP and MBP values in both groups were planned to be the primary outcomes of the study. In addition, findings such as DBP value, nausea and dizziness will also be recorded as secondary outcomes.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Treatment of Sympathetic Blockade During Spinal Anesthesia in Cesarian Section Patients With Low-dose, Slow-administered Preemptive Atropine
Anticipated Study Start Date :
Jun 7, 2023
Anticipated Primary Completion Date :
Dec 10, 2023
Anticipated Study Completion Date :
Dec 10, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Efedrine Group

For sympathetic blockade (SBP<90) if developed in patients in the ephedrine group, a bolus dose of 5 mg/mL ephedrine would be used and repeated if necessary. In case of development of bradycardia (<65/min) in this group, Atropine 0.5 mg/mL would be planned to be administered and repeated if necessary.

Drug: Ephedrine
For sympathetic blockade (SBP<90) developed in patients in the ephedrine group, a bolus dose of 5 mg/mL ephedrine was used and repeated if necessary.

Experimental: Preemptive Atropine Group

In the atropine group, it will planned to administer 0.4 mg/4mL diluted atropine in 20 seconds(10mcg/kg), as a slow bolus as bradycardia would expected (10% reduction in peak heart rate after spinal anesthesia). In this group if SBP<90 despite slow dose atropine administration; it will be planed to give efedrine as bolus of 5 mg/mL. And for bradicardia (HR<65/min) it will be planed to give Atropine 0.5 mg/mL.

Drug: Slow dose preemptive Atropine
it will planned to administer 0.4 mg/4mL diluted atropine in 20 seconds(10mcg/kg), as a slow bolus as bradycardia would expected (10% reduction in peak heart rate after spinal anesthesia)
Other Names:
  • Atropine
  • Outcome Measures

    Primary Outcome Measures

    1. Heart rate [1. minunte after spinal block]

      Heart rate

    2. Heart rate [4. minute after spinal block]

      Heart rate

    3. Heart rate [7. minute after spinal block]

      Heart rate

    4. Heart rate [9. minute after spinal block]

      Heart rate

    5. Heart rate [12. minute after spinal block]

      Heart rate

    6. Heart rate [15. minute after spinal block]

      Heart rate

    7. Systolic Blood pressure [1. minute after spinal block]

      Systolic Blood pressure

    8. Systolic Blood pressure [4. minute after spinal block]

      Systolic Blood pressure

    9. Systolic Blood pressure [7. minute after spinal block]

      Systolic Blood pressure

    10. Systolic Blood pressure [9. minute after spinal block]

      Systolic Blood pressure

    11. Systolic Blood pressure [12. minute after spinal block]

      Systolic Blood pressure

    12. Systolic Blood pressure [15. minute after spinal block]

      Systolic Blood pressure

    13. Mean Blood Pressure [1. minute after spinal block]

      Mean Blood Pressure

    14. Mean Blood Pressure [4. minute after spinal block]

      Mean Blood Pressure

    15. Mean Blood Pressure [7. minute after spinal block]

      Mean Blood Pressure

    16. Mean Blood Pressure [9. minute after spinal block]

      Mean Blood Pressure

    17. Mean Blood Pressure [12. minute after spinal block]

      Mean Blood Pressure

    18. Mean Blood Pressure [15. minute after spinal block]

      Mean Blood Pressure

    19. Efedrine Consumption [1. minute after spinal block]

      Efedrine Consumption in the first 15 minutes after the spinal block

    20. Efedrine Consumption [4. minute after spinal block]

      Efedrine Consumption in the first 15 minutes after the spinal block

    21. Efedrine Consumption [7. minute after spinal block]

      Efedrine Consumption in the first 15 minutes after the spinal block

    22. Efedrine Consumption [9. minute after spinal block]

      Efedrine Consumption in the first 15 minutes after the spinal block

    23. Efedrine Consumption [12. minute after spinal block]

      Efedrine Consumption in the first 15 minutes after the spinal block

    24. Efedrine Consumption [15. minute after spinal block]

      Efedrine Consumption in the first 15 minutes after the spinal block

    25. Atropine Consumption [1. minute after spinal block]

      Atropine Consumption in the first 15 minutes after the spinal block

    26. Atropine Consumption [4. minute after spinal block]

      Atropine Consumption in the first 15 minutes after the spinal block

    27. Atropine Consumption [7. minute after spinal block]

      Atropine Consumption in the first 15 minutes after the spinal block

    28. Atropine Consumption [9. minute after spinal block]

      Atropine Consumption in the first 15 minutes after the spinal block

    29. Atropine Consumption [12. minute after spinal block]

      Atropine Consumption in the first 15 minutes after the spinal block

    30. Atropine Consumption [15. minute after spinal block]

      Atropine Consumption in the first 15 minutes after the spinal block

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 40 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    ASA Ι-ΙΙ Ages 18-40 Weight 55-105 kg Height 150-175 cm

    Exclusion Criteria:

    Who does not require drug administration with fluid therapy Whose hemodynamic changes are within an acceptable range Diabetes COPD Hypertension BMI>34 Preeclampsia/eclampsia Multiple pregnancies Pathology in the fetus Hematological problems such as Rh incompatibility Hypersensitivity to local anesthetics Contraindications to regional anesthesia

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Abant Izzet Baysal University

    Investigators

    • Principal Investigator: Akcan Akkaya, MD., Bolşu Abant Izzet Baysal university Medical School, Anesthesiology and Reanimation D.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Akcan AKKAYA Prof. MD., Professor Dr., Abant Izzet Baysal University
    ClinicalTrials.gov Identifier:
    NCT05892913
    Other Study ID Numbers:
    • BAIBU-Anesthesia-AA-03
    First Posted:
    Jun 7, 2023
    Last Update Posted:
    Jun 8, 2023
    Last Verified:
    Jun 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Akcan AKKAYA Prof. MD., Professor Dr., Abant Izzet Baysal University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 8, 2023